Tweets
RT @minidey #OP0342 Interim real-world ASTER data showed anifrolumab improved overall SLEDAI-2K scores & reduced disease activity across multiple organ systems over 12 months, particularly mucocutaneous & MSK domains. Nearly 30% achieved SLEDAI-2K=0 at 1 year. #EULAR2026
Dr. John Cush @RheumNow ( View Tweet )
13 hours 9 minutes ago
RT @aurelierheumo Failure to achieve early remission RA asso w/ non-inflammatory pain
NORD-STAR 526 early RA pts)
no remission at 24 wks increased risk of 48wk
• unacceptable pain (OR ~6)
• refractory pain (OR ~6)
• fibromyalgic RA (OR ~16)
Signal strongest w/ very early
Dr. John Cush @RheumNow ( View Tweet )
14 hours 39 minutes ago
EULAR26: Reports on Systemic Sclerosis
https://t.co/knZZlMYlen https://t.co/0wul0yaw4m
Dr. John Cush @RheumNow ( View Tweet )
18 hours 8 minutes ago
Generic Tofacitinib (6.26.2026)
Dr. Jack Cush reviews the news and journal articles from https://t.co/V10S4oVFsv. Updates on tofacitinib, CAR-T therapy and AI.
https://t.co/DNWh7taaN6 https://t.co/4r5fuooqWn
Dr. John Cush @RheumNow ( View Tweet )
21 hours 39 minutes ago
EULAR26: Updates in SLE and APS
Severe refractory systemic lupus erythematosus (srSLE) is a clinical state conceptualised as persistent high disease activity despite standard care with glucocorticoids and immunosuppressants.
https://t.co/DP7gPvlGhU https://t.co/imN6Xb7QGT
Dr. John Cush @RheumNow ( View Tweet )
23 hours 8 minutes ago
Is it all over for avacopan? #Vasculitis
https://t.co/1sFUidC6Cw
Rheuma Doc @LastManStand85 ( View Tweet )
1 day ago
RT @jiharheum : ETA+MTX vs triple therapy after MTX failure in #RA: machine learning-emulated RACAT trial (n=3,472 VA pts) confirms ETA+MTX modestly better overall. But smoking matters: benefit disappears in current smokers. Precision medicine from RWD. #EULAR2026 POS0255
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
RT @drminidey
#OP0208 #EULAR2026: phase 3 COURAGE-RA trial showed strong efficacy for selective JAK1 inhibitor zemprocitinib in D2T RA after bDMARD failure. Responses were rapid (from week 2), sustained through week 24 and achieved with a reassuring safety profile.
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
Which is NOT a key feature of inflammatory back pain: relief with activity; morning stiffness; age under 40 years; unilateral pain? Test your knowledge in this week's RheumIQ quiz at https://t.co/z8mLbcgE5D. https://t.co/tOdPfEBJa4
Dr. John Cush @RheumNow ( View Tweet )
1 day 21 hours ago
Obexelimab in IgG4-Related Disease: INDIGO Trial
Dr. Henrique Dalmolin reports on abstract OP018 from EULAR 2026.
https://t.co/Wid9ZzESae https://t.co/Qo4y8ebkOn
Dr. John Cush @RheumNow ( View Tweet )
1 day 23 hours ago
2026 Guidelines for the Treatment of Axial Spondyloarthritis
New guidelines offer clinicians and patients clearer directions on diagnostic workup, treatment selection, and long-term disease management, while emphasizing shared decision-making due to ongoing evidence gap. https://t.co/SUFnOMAUw8
Dr. John Cush @RheumNow ( View Tweet )
2 days ago
Self-Directed Cognitive Behavioral Therapy for Chronic Pain
Is self-directed cognitive behavioral therapy (CBT) when augmented with asynchronous, personalized feedback for chronic pain (CBT-CP) superior to clinician-delivered CBT-CP?
https://t.co/P2DDvCiLNL https://t.co/hyAArEG6V1
Dr. John Cush @RheumNow ( View Tweet )
2 days ago
